Biomarin Pharmaceutical (BMRN) Change in Accured Expenses (2009 - 2026)

Biomarin Pharmaceutical (BMRN) has 18 years of Change in Accured Expenses data on file, last reported at $8.7 million in Q1 2026.

• Quarterly Change in Accured Expenses rose 427.83% year-over-year to $8.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $26.2 million (down 63.12% YoY) and the FY2025 annual result came in at $14.9 million, up 0.73% from the prior year.
• Change in Accured Expenses improved to $8.7 million in Q1 2026, from -$7.0 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $73.1 million in Q3 2022 to a low of -$78.1 million in Q1 2022.
• A 5-year average of $9.8 million and a median of $4.5 million in 2024 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses slumped 3491.62% — and 2024, when it jumped 2212.28%.
• Tracing BMRN's Change in Accured Expenses over 5 years: stood at $62.3 million in 2022, then decreased by 12.45% to $54.5 million in 2023, then sank by 91.69% to $4.5 million in 2024, then plunged by 254.96% to -$7.0 million in 2025, then soared by 223.94% to $8.7 million in 2026.
• The last three Change in Accured Expenses figures came in at $8.7 million (Q1 2026), -$7.0 million (Q4 2025), and $16.4 million (Q3 2025), per Business Quant data.